|Bid||14.09 x 800|
|Ask||15.99 x 1100|
|Day's Range||13.75 - 14.45|
|52 Week Range||8.50 - 23.64|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.86|
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero’s potentiator p
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) is possibly approaching a major achievement in its business, so we would like...
When you offer your home as a short-term rental through services like Airbnb, HomeAway, and VRBO, there are ways you can keep your income taxes to a minimum.